VT
Vitrolife AB (publ)
VTRLY · OTC
$9.50 +0.00% (+$0.00)
Market Cap 12.9B kr
P/E Ratio -
Div. Yield 1.24%
ROE 53.34%
Bulios Fair Price
$7.04
25.9% downside
Current Price
$9.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VTRLY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
68 /100
Cheap P/B 1.59x
P/FCF 21.34x
P/S 3.82x
Growth
15 /100
Declining FCF growth 14.50%
Book val. growth 22.16%
Rev. growth 2.08%
Profitability
50 /100
Moderate FCF margin 17.92%
Op. margin 141.11%
Gross margin 57.34%
Quality
4 /100
Poor Asset turnover 0.30x
ROA 44.08%
ROIC 45.57%
Debt
69 /100
Low Current ratio 3.64x
Int. coverage -127.26x
Debt/Equity 0.20x
Stability
35 /100
Moderate Profitable years 0
EPS volatility 671.56%
Beta 1.71x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VTRLY
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Bronwyn Brophy O'Connor
Employees
1,151
Headquarters
Gothenburg